PAI LIFE SCIENCES INC
LFGuard™, a recombinant fusion protein vaccine (Bm-HAXT with TLR4 agonist adjuvant) for prophylaxis of lymphatic filariasis
- Sector
- Biotech
- Headquarters
- Seattle, WA
- Total capital
- $25M
- Federal grants
- $19.2M
- 29 awards · 2015–2026
- Rank in peer group#177 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $5.8M
- 7 awards · Health and Human S
- Rank in Biotech#73 of 4373
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Vaccine for Lymphatic Filariasis, LFGuard™$714K
- Federal grantHealth and Human S · Phase II · A Vaccine for Lymphatic Filariasis, LFGuard™$453K
- Federal grantHealth and Human S · Phase I · Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield$295K
- Federal grantHealth and Human S · Phase II · A Vaccine for Lymphatic Filariasis, LFGuard™$995K
- Federal grantHealth and Human S · Phase I · Evaluation of a Next Generation SchistoShield Vaccine$300K
- Federal grantHealth and Human S · Phase II · A Vaccine for Lymphatic Filariasis, LFGuard™$1M
- Federal grantHealth and Human S · Phase II · A Vaccine for Schistosomiasis, "SchistoShield"$506K
Show 29 earlier federal awards
- Federal contractHealth and Human S · Late Stage Adjuvant Mimics Based On TLR4 Agonists$598K
- Federal grantHealth and Human S · Phase I · Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines$243K
- Federal grantHealth and Human S · Phase II · A Vaccine for Lymphatic Filariasis, LFGuard™$1M
- Federal grantHealth and Human S · Phase II · A Vaccine for Schistosomiasis, "SchistoShield"$506K
- Federal grantHealth and Human S · Phase II · JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer$557K
- Federal grantHealth and Human S · Phase II · A Vaccine for Lymphatic Filariasis, LFGuard™$1M
- Federal grantHealth and Human S · Phase II · A Vaccine for Lymphatic Filariasis, LFGuard™$3M
- Federal grantHealth and Human S · Phase II · A Vaccine for Schistosomiasis, "SchistoShield"$707K
- Federal grantHealth and Human S · Phase II · JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer$1.3M
- Federal grantHealth and Human S · Phase II · JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer$721K
- Federal contractHealth and Human S · Phase II - Development Of A Prophylactic Onchocerciasis Vaccine$2.3M
- Federal contractHealth and Human S · The Objective Of This Contract Is To Develop Preclinical Rabbit Immunogenicity Data Demonstrating Efficacy Of The Selfadjuvantingand Self-amplifying Rna Platform.$299K
- Federal grantHealth and Human S · Phase I · Process Development for a Lymphatic Filariasis Vaccine, (LFGuard)$225K
- Federal grantHealth and Human S · Phase I · Process Development for a Lymphatic Filariasis Vaccine, (LFGuard™)$225K
- Federal grantHealth and Human S · Phase I · Production and Validation of Sj-p80 as a Veterinary Schistosomiasis Vaccine$225K
- Federal grantHealth and Human S · Phase II · A Vaccine for Schistosomiasis, "SchistoShield"$1.3M
- Federal grantHealth and Human S · Phase I · CruziScreen a recombinant antigen based screening test for Chagas disease$157K
- Federal grantHealth and Human S · Phase I · CruziScreen, a recombinant antigen-based screening test for Chagas disease$157K
- Federal grantHealth and Human S · Phase I · Development of an Innovative, Effective RNA-based Vaccine for Chikungunya Virus$225K
- Federal grantHealth and Human S · Phase II · A Vaccine for Schistosomiasis, "SchistoShield"$1.4M
- Federal grantHealth and Human S · Phase I · JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer$200K
- Federal grantHealth and Human S · Phase I · JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer$200K
- Federal contractHealth and Human S · Igf::ot::igf Title - Development Of A Prophylactic Onchocerciasis Vaccine$442K
- Federal contractHealth and Human S · Igf::ot::igf Title - Combining Parasite And Vector Components For Development Of A Leishmania Vaccine$444K
- Federal grantHealth and Human S · Phase I · A recombinant protein that increases engraftment of hematopoietic stem cells$209K
- Federal grantHealth and Human S · Phase II · A Vaccine for Schistosomiasis, "SchistoShield"$1.2M
- Federal contractHealth and Human S · Igf::ot::igf Inhaled Drug Combination For Tuberculosis Therapy$1.5M
- Federal grantHealth and Human S · Phase I · Immuno-Chemotherapy to Shorten TB Treatment$300K
- Federal contractHealth and Human S · Igf::ot::igf Aerosolized Delivery Of Anti-tubercular Drugs$211K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#177 · top 34%
- Linked publications#29 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 5- PendingVaccine And Methods For Preventing Filariasis And DirofilariasisUSPTOApplication 18275463
- PendingSchistosoma Vaccine Antigen Modifications And Uses ThereofUSPTOApplication 63733169
- PendingVaccine And Methods For Preventing Filariasis And DirofilariasisUSPTOApplication PCTUS2022014894
Show all 5 patent records
- Vaccine And Methods For Preventing Filariasis And DirofilariasisApr 11, 2024 · Application 18275463Pending
- Schistosoma Vaccine Antigen Modifications And Uses ThereofApplication 63733169Pending
- Vaccine And Methods For Preventing Filariasis And DirofilariasisApplication PCTUS2022014894Pending
- Vaccine And Methods For Preventing Filariasis And DirofilariasisApplication 63145153Pending
- Conjugatable Desmoglein 2 (DSG2) Binding Proteins And Uses ThereforApplication PCTUS2019015280Pending
Recent research by its founders
- A next-generation human lymphatic filariasis vaccine candidate, rBmHAXT, for clinical development20260 cites
- Intratumoral injection of a novel TLR4 agonist elicits infiltration by immune effector cells in a canine soft tissue sarcoma: An Immunologic Case Study20260 cites
- Junction opener enables CAR T cell treatment of solid tumors20260 cites
Related companies, and why
- MEDIGEN, INC.Similar federal contract value in Biotech · $7M in contracts
- REJUVENATE BIO INCSimilar federal contract value in Biotech · $6.3M in contracts
- BCN BIOSCIENCES LLCSimilar federal contract value in Biotech · $6.2M in contracts
- 60 DEGREES PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $5.8M in contracts
- FABRICO TECHNOLOGY, INC.Similar federal contract value in Biotech · $5.6M in contracts
- Shuttle Pharmaceuticals, Inc.Similar federal contract value in Biotech · $5.5M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .